New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
14:41 EDTACT, QCOR, MNKFDA approval of generic Exalgo negative for Mallinckrodt, says BMO Capital
BMO Capital thinks the FDA's approval of Actavisí (ACT) generic version of Exalgo was expected, but the firm still views it as a near-term negative for Mallinckrodt (MNK). BMO expects Mallinckrodt's raised guidance and pending accretive Questcor (QCOR) deal to support the stock longer-term and maintains an Outperform rating on Mallinckrodt.
News For ACT;QCOR;MNK From The Last 14 Days
Check below for free stories on ACT;QCOR;MNK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 23, 2014
10:02 EDTMNK, ACTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTMNK, ACTDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTACTActavis initiated with a Buy at Deutsche Bank
Subscribe for More Information
16:09 EDTMNKMallinckrodt initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
16:36 EDTACTActavis and Medicines360 announce FDA acceptance of Levosert NDA
Subscribe for More Information
07:36 EDTQCOR, MNKMallinckrodt price target raised to $95 from $85 at Jefferies
Subscribe for More Information
July 17, 2014
15:42 EDTACTDepomed says Actavis preliminarily enjoined from marketing generic Gralise
Subscribe for More Information
11:12 EDTQCOROptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTMNKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
July 16, 2014
16:13 EDTMNK, QCORMallinckrodt initiated with an Outperform, $100 target at Oppenheimer
Oppenheimer believes Mallinckrodt's (MNK) acquisition of Questcor (QCOR) provides sustainable high-growth revenue potential. It believes the company bought Acthar at an attractive valuation. Opco started shares of Mallinckrodt with an Outperform rating and $100 price target.
16:09 EDTMNKMallinckrodt initiated with an Outperform at Oppenheimer
Target $100.
11:28 EDTACTLeon Cooperman gives 12 stock picks at CNBC conference
Subscribe for More Information
11:16 EDTACTCooperman lists Actavis, Citigroup, KKR among top-picks, CNBC says
Subscribe for More Information
10:35 EDTQCOROptions with decreasing implied volatility
Subscribe for More Information
09:12 EDTACTLeerink healthcare analyst holds an analyst/industry conference call
Subscribe for More Information
July 14, 2014
15:09 EDTQCOR, MNKQuestcor rises after S-4 effective, interest from other suitors disclosed
Subscribe for More Information
07:04 EDTQCOR, MNKMallinckrodt and Questcor update transaction
Mallinckrodt (MNK) and Questcor (QCOR) announced that the registration statement on Form S-4 filed with the SEC by Mallinckrodt on May 16 and amended on July 11 which includes a joint proxy statement of Mallinckrodt and Questcor that also constitutes a prospectus of Mallinckrodt, was declared effective on July 11. The companies have also each scheduled shareholder meetings on August 14 for shareholders of record on July 9 to consider (i) in the case of Mallinckrodt, its proposal to issue its ordinary shares in connection with its proposed acquisition of Questcor and (ii) in the case of Questcor, approval of the merger agreement with Mallinckrodt and related matters. The transaction is currently expected to be completed in August.
July 11, 2014
16:31 EDTACTActavis confirms generic Diclegis patent challenge
Subscribe for More Information
09:09 EDTQCOROn The Fly: Pre-market Movers
Subscribe for More Information
06:39 EDTMNK, QCORQuestcor reports Acthar adverse effects data, NY Times says
The number of patients who reported an adverse effect last year while taking Questcor's (QCOR) Acthar drug amounted to almost 5% of prescriptions dispensed, the company stated in a regulatory filing released yesterday, according to The New York Times. The filing marked the first time that the company has disclosed any difficulties experienced by Acthar patients, the newspaper added. Questcor has agreed to be bought by Mallinckrodt (MNK). Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use